These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 38104877)

  • 1. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
    Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
    J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
    Ruan Z; Liang M; Shang L; Lai M; Deng X; Su X
    Pancreatology; 2021 Apr; 21(3):630-641. PubMed ID: 33707115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo.
    Xu H; Chen Y; Li Z; Zhang H; Liu J; Han J
    Eur J Pharmacol; 2022 Sep; 930():175154. PubMed ID: 35868447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-responsive lncRNA MIR155HG promotes PD-L1 expression in hepatocellular carcinoma cells by enhancing HIF-1α mRNA stability.
    Qiu J; Zhong F; Zhang Z; Pan B; Ye D; Zhang X; Yao Y; Luo Y; Wang X; Tang N
    Int Immunopharmacol; 2024 Jul; 136():112415. PubMed ID: 38850791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma.
    Lin L; Chen S; Wang H; Gao B; Kallakury B; Bhuvaneshwar K; Cahn K; Gusev Y; Wang X; Wu Y; Marshall JL; Zhi X; He AR
    Theranostics; 2021; 11(9):4232-4250. PubMed ID: 33754058
    [No Abstract]   [Full Text] [Related]  

  • 6. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer.
    Zuo HX; Jin Y; Wang Z; Li MY; Zhang ZH; Wang JY; Xing Y; Ri MH; Jin CH; Xu GH; Piao LX; Ma J; Jin X
    J Ethnopharmacol; 2020 Jul; 257():112835. PubMed ID: 32278762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
    Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
    Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.
    Chen J; Feng W; Sun M; Huang W; Wang G; Chen X; Yin Y; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Gastroenterology; 2024 Jul; 167(2):264-280. PubMed ID: 38417530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Si Jun Zi decoction inhibits the growth of lung cancer by reducing the expression of PD-L1 through TLR4/MyD88/NF-κB pathway.
    Zhao W; Liu Z; Zhang Z; Chen Z; Liu J; Sun P; Li Y; Qi D; Zhang Z
    J Ethnopharmacol; 2024 Jan; 318(Pt A):116948. PubMed ID: 37482260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: In Vivo and in Vitro Experimentation.
    Takaki H; Hirata Y; Ueshima E; Kodama H; Matsumoto S; Wada R; Suzuki H; Nakasho K; Yamakado K
    J Vasc Interv Radiol; 2020 Sep; 31(9):1475-1482.e2. PubMed ID: 32800663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 13. Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma.
    Deng Z; Teng YJ; Zhou Q; Ouyang ZG; Hu YX; Long HP; Hu MJ; Mei S; Lin FX; Dai XJ; Zhang BY; Feng T; Tian XF
    World J Gastrointest Oncol; 2021 Nov; 13(11):1725-1740. PubMed ID: 34853646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.
    Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tibetan medicine Qi-Sai-Er-Sang-Dang-Song Decoction inhibits TNF-α-induced rheumatoid arthritis in human fibroblast-like synoviocytes via regulating NOTCH1/NF-κB/NLRP3 pathway.
    Su J; Tao Y; Liu J; Sun J; Zeng Y; Meng X; Fan G; Zhang Y
    J Ethnopharmacol; 2023 Jun; 310():116402. PubMed ID: 36966850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression.
    Rong W; Wan N; Zheng X; Shi G; Jiang C; Pan K; Gao M; Yin Z; Gao ZJ; Zhang J
    Phytomedicine; 2022 Jan; 95():153867. PubMed ID: 34923234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma.
    Chen ZQ; Zuo XL; Cai J; Zhang Y; Han GY; Zhang L; Ding WZ; Wu JD; Wang XH
    Exp Hematol Oncol; 2023 Feb; 12(1):17. PubMed ID: 36747292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systems pharmacology reveals the mechanism of Astragaloside IV in improving immune activity on cyclophosphamide-induced immunosuppressed mice.
    Yao J; Liu J; He Y; Liu L; Xu Z; Lin X; Liu N; Kai G
    J Ethnopharmacol; 2023 Sep; 313():116533. PubMed ID: 37100262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment.
    Li H; You J; Wei Y; Zheng L; Yang J; Xu J; Li Y; Li Z; Yang X; Yi C
    Phytomedicine; 2024 Jan; 123():155189. PubMed ID: 37984124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway.
    Liu Y; Xu Q; Deng F; Zheng Z; Luo J; Wang P; Zhou J; Lu X; Zhang L; Chen Z; Zhang Q; Chen Q; Zuo D
    J Exp Clin Cancer Res; 2023 Feb; 42(1):38. PubMed ID: 36721234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.